Javascript must be enabled to continue!
Theranostics Nuclear Medicine in Prostate Cancer
View through CrossRef
Theranostic Nuclear Medicine is based on the idea of combining the same molecule (or drug) with different radioisotopes for both diagnosis and treatment, a concept that emerged in the early 1940s with the use of radioactive iodine for thyroid diseases. Theranostic Nuclear Medicine has since expanded to diseases of higher incidence, such as prostate cancer, with several imaging methods used to assess the extent of the disease and the corresponding radiopharmaceuticals used for treatment. For example, by detecting osteoblastic metastases by bone scintigraphy, corresponding radiopharmaceuticals with therapeutic properties can be administered to eliminate or reduce pain associated with metastases and/or determine overall survival gain. The purpose of this review is to discuss the role of Theranostic Nuclear Medicine in prostate cancer, addressing the main diagnostic imaging studies with their corresponding treatments in the Theranostic model.
Title: Theranostics Nuclear Medicine in Prostate Cancer
Description:
Theranostic Nuclear Medicine is based on the idea of combining the same molecule (or drug) with different radioisotopes for both diagnosis and treatment, a concept that emerged in the early 1940s with the use of radioactive iodine for thyroid diseases.
Theranostic Nuclear Medicine has since expanded to diseases of higher incidence, such as prostate cancer, with several imaging methods used to assess the extent of the disease and the corresponding radiopharmaceuticals used for treatment.
For example, by detecting osteoblastic metastases by bone scintigraphy, corresponding radiopharmaceuticals with therapeutic properties can be administered to eliminate or reduce pain associated with metastases and/or determine overall survival gain.
The purpose of this review is to discuss the role of Theranostic Nuclear Medicine in prostate cancer, addressing the main diagnostic imaging studies with their corresponding treatments in the Theranostic model.
Related Results
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract
Background: Prostate cancer is the second most frequent malignancy (after lung cancer) in men worldwide. It is the third most common cancer in men in Algeri...
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract
The human olfactomedin 4 gene (OLFM4) encodes an olfactomedin-related glycoprotein, which our group first cloned and characterized in myeloid cells and mapp...
Abstract 1568: The role of CCL2 CCL17 CCL22-CCR4 axis in prostate cancer metastasis
Abstract 1568: The role of CCL2 CCL17 CCL22-CCR4 axis in prostate cancer metastasis
Abstract
BACKGROUND: Multiple steps and factors are involved in prostate carcinogenesis and tumor progression. The early studies have found that tumor-associated mac...
Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group
Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group
ImportanceAdvocates for removing the cancer label from grade group 1 (GG1) prostate cancer detected on biopsy primarily base their argument on the observation that when only GG1 is...
Study on Early Prostate Cancer Antigen (EPCA) and existent risk factors of prostate cancer, Sudan: A case-control study
Study on Early Prostate Cancer Antigen (EPCA) and existent risk factors of prostate cancer, Sudan: A case-control study
Background: Early prostate cancer antigen (EPCA), a nuclear matrix protein, has recently been recommended as a hopeful biomarker for early prostate carcinogenesis. Objectives: To e...
Data from Dietary Fructose Promotes Prostate Cancer Growth
Data from Dietary Fructose Promotes Prostate Cancer Growth
<div>Abstract<p>Clinical localization of primary tumors and sites of metastasis by PET is based on the enhanced cellular uptake of 2-deoxy-2-[<sup>18</sup>F...
PROSTATE CANCER EPIDEMIOLOGY IN THE EAST KAZAKHSTAN REGION, 2010-2019
PROSTATE CANCER EPIDEMIOLOGY IN THE EAST KAZAKHSTAN REGION, 2010-2019
Relevance: From 2010 to 2019, prostate cancer morbidity increased, and prostate cancer mortality decreased in Kazakhstan. The peak incidence was observed in patients aged 70 years ...
PROSTATE CANCER EPIDEMIOLOGY IN THE EAST KAZAKHSTAN REGION, 2010-2019
PROSTATE CANCER EPIDEMIOLOGY IN THE EAST KAZAKHSTAN REGION, 2010-2019
Relevance: From 2010 to 2019, prostate cancer morbidity increased, and prostate cancer mortality decreased in Kazakhstan. The peak incidence was observed in patients aged 70 years ...

